tradingkey.logo

Fortrea Holdings Inc

FTRE
查看詳細走勢圖
14.650USD
+0.850+6.16%
收盤 02/06, 16:00美東報價延遲15分鐘
1.35B總市值
虧損本益比TTM

Fortrea Holdings Inc

14.650
+0.850+6.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+6.16%

5天

-12.85%

1月

-16.24%

6月

+102.35%

今年開始到現在

-15.07%

1年

-1.74%

查看詳細走勢圖

TradingKey Fortrea Holdings Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Fortrea Holdings Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名63/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為16.80。中期看,股價處於上升通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Fortrea Holdings Inc評分

相關信息

行業排名
63 / 392
全市場排名
183 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Fortrea Holdings Inc亮點

亮點風險
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

分析師目標

基於 11 分析師
持有
評級
16.800
目標均價
+4.61%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Fortrea Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Fortrea Holdings Inc簡介

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
公司代碼FTRE
公司Fortrea Holdings Inc
CEOThakrala (Anshul)
網址https://www.fortrea.com/
KeyAI